RedHill Biopharma Ltd. (RDHL) Submits New Drug Application to U.S. FDA for RHB-103 Anti-Migraine Oral Thin Film
3/27/2013 11:07:16 AM
More...
|
RedHill Biopharma Ltd. (RDHL) Receives Positive Feedback From a Scientific Advice Meeting in Europe Regarding RHB-101 (Hypertension) Marketing Application Plan
3/19/2013 11:14:12 AM
More...
|
RedHill Biopharma Ltd. (RDHL) to Present at the 25th Annual ROTH Conference
3/6/2013 11:07:31 AM
More...
|
RedHill Biopharma Ltd. (RDHL) Reports 2012 Fourth Quarter And Year-End Results
2/20/2013 11:31:10 AM
More...
|
RedHill Biopharma Ltd. (RDHL) Announces Issuance of New U.S. Patent and Provides Update on RHB-104 for Treatment of Crohn's Disease
1/7/2013 9:53:03 AM
More...
|
RedHill Biopharma Ltd. (RDHL) Announces NASDAQ Listing and Commencement of Trading Under the Ticker "RDHL"
12/27/2012 9:02:16 AM
More...
|
RedHill Biopharma Ltd. Announces Successful Completion of $6.5 Million Private Placement
12/6/2012 11:03:42 AM
More...
|
RedHill Biopharma Ltd. Announces Successful Pre-NDA Meeting Wth FDA Toward a Filing of a U.S. New Drug Application (NDA) for its RHB-103 Anti-Migraine Oral Thin-Film
11/9/2012 11:10:23 AM
More...
|
RedHill Biopharma Ltd. Announces a Successful Pivotal Bioequivalence Trial with RHB-103 for the Treatment of Migraine
5/29/2012 9:57:01 AM
More...
|
RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months
4/24/2012 10:29:21 AM
More...
|
|